Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.
Hisao ImaiSatoshi WasamotoTakeshi TsudaYoshiaki NagaiTakayuki KishikawaKen MasubuchiTakashi OsakiYosuke MiuraYukihiro UmedaAkihiro OnoHiroyuki MinemuraYutaka YamadaJunichi NakagawaYuki KozuHirokazu TaniguchiHiromitsu OhtaTakashi KasaiKyoichi KairaHiroshi KagamuPublished in: Thoracic cancer (2023)
The NLR significantly predicted PFS and OS, whereas BMI predicted OS, in individuals who initially received Pemb-Plt-PEM for non-sq NSCLC. These factors might be prognosis predictors in non-sq NSCLC.